–  The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib) at week 12 and week 52 versus placebo¹
–  Clinical response was achieved by significantly more patients treated with RINVOQ (upadacitinib) versus placebo as early as week 2 in induction studies¹
–  This indication marks the seventh FDA approval for RINVOQ across gastroenterology, rheumatology and dermatology¹

IRVINE, Calif., May 15, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of SKINVIVE™ by JUVÉDERM^® to improve skin smoothness of the cheeks in adults over the age of 21.¹ SKINVIVE™ by JUVÉDERM^® is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the U.S. with results lasting through six months with optimal treatment.¹

-  Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ^®) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS^®) in treating functional constipation in pediatric patients aged 6 to 17 years 

NORTH CHICAGO, Ill., May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00 a.m. Central time.

NORTH CHICAGO, Ill., April 27, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2023.

NORTH CHICAGO, Ill., April 21, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of oral preventive medications. The results of the study demonstrated adult patients in the atogepant 60 mg once daily (QD) arm experienced a decrease of 4.20 days in their mean monthly migraine days (MMDs) across the 12-week treatment period, which was statistically significantly greater than the 1.85 day reduction observed in the placebo arm (p<0.0001). The data will be presented during the Emerging Science session on Tuesday, April 25, at the 2023 American Academy of Neurology (AAN) Annual Meeting taking place in Boston, Massachusetts.

IRVINE, Calif., April 18, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, supports women plastic surgeons and the development of current and future leaders in science, healthcare, and medicine with LIMITLESS, an ongoing initiative in partnership with American Society of Plastic Surgeons (ASPS), The Aesthetic Society and the American Hernia Society. LIMITLESS was developed three years ago as a program to highlight women's achievements in plastic surgery while also providing education, mentorship and empowerment.

NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of QULIPTA^® (atogepant) for the preventive treatment of migraine in adults. The approval makes QULIPTA the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine. People living with chronic migraine experience headaches for 15 or more days per month, with at least eight of those days associated with migraine.¹

–  Seventh approved indication for RINVOQ in the European Union (EU) and the first and only oral Janus Kinase (JAK) inhibitor approved to treat adult patients with moderately to severely active Crohn's disease

NORTH CHICAGO, Ill., April 12, 2023 /PRNewswire/ -- AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a program that is making a difference in the lives of young adults with CF and their families, is now accepting applications for the 2023-2024 academic school year. Eligible undergraduate and graduate students are invited to apply for the scholarship until May 24, 2023 at 11:00 a.m. U.S. Eastern Time by visiting www.AbbVieCFScholarship.com. Students can either apply online or complete and mail a printed application.